Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
NCT01412359 is an expanded access program sponsored by Jeffrey Rudolph. As of 21 Nov 2026, it has the registry status "Approved for marketing". It studies Omegaven® in Total Parenteral Nutrition-induced Cholestasis. The registry lists 1 site in 1 country.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01412359 |
| Status | Approved for marketing |
| Study type | Expanded access program |
| Lead sponsor | Jeffrey Rudolph |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Total Parenteral Nutrition-induced Cholestasis |
| Drugs | Omegaven® |
| Last update posted | 24 Apr 2019 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jeffrey A Rudolph, MD
University of Pittsburgh
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children's Hospital of Pittsburgh of Upmc
Pittsburgh
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01412359
Each answer restates registry values shown on this page.
What is NCT01412359?
NCT01412359 is an expanded access program sponsored by Jeffrey Rudolph. It studies Omegaven® in Total Parenteral Nutrition-induced Cholestasis.
Who leads NCT01412359?
The registry names Jeffrey A Rudolph, MD (principal investigator, University of Pittsburgh) as the overall official.
Where does NCT01412359 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01412359 study?
The registered drug and biological interventions are Omegaven®.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.